Synopsis: 

Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport’s cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug development. Abe also shares his dynamic leadership journey, offering insights into the biotech industry’s future and how innovative approaches are delivering life-changing treatments. Don’t miss this powerful discussion on the future of precision medicine and the hope it brings to patients with neurological conditions.

Biography:

Abe brings nearly two decades of biopharmaceutical industry experience to Rapport. He served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston. He earned his bachelor’s degree from Ithaca College and Master of Business Administration from Suffolk University’s Sawyer School of Management.

Precision Neuroscience Breakthroughs: Abe Ceesay, CEO of Rapport Therapeutics I Future of Biotech

Synopsis: 

In this episode of Biotech 2050, Alex Martin, CEO of Abcuro, sits down with host Rahul Chaturvedi to share his inspiring journey from aspiring actor to biotech trailblazer. Alex reveals how his unique background shaped his leadership approach as he drives Abcuro’s groundbreaking work on Inclusion Body Myositis (IBM), a rare muscle disease with no current treatments. He offers valuable insights for biotech CEOs on navigating the complexities of fundraising, building mission-driven teams, and fostering productive relationships with boards. Tune in to discover how Alex is leading Abcuro to the forefront of biotech innovation and making a profound impact on patient lives.

Biography:

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard.

Inside the Journey of Abcuro: CEO Alex Martin on Leadership, IBM, and the Future of Biotech

Biotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, which targets Parkinson's disease by aiming for disease modification rather than symptom management. Gene also discusses the challenges of biotech leadership, running clinical trials, and navigating the financial landscape, highlighting the dynamic intersection of science, business, and innovation in neurodegenerative diseases.

Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs

Synopsis:
 
Rob Williamson, CEO of Triumvira, joins Biotech 2050 host, Rahul Chaturvedi, to discuss his dynamic career from economics to biotech, tackling the volatile capital markets, and navigating high-stakes decisions in cell therapy. He shares insights on therapeutic developments in cell therapy, the pressures of solid tumor research, and the evolving biotech ecosystem. A deep dive into biotech board dynamics, funding strategies, and the potential of AI in healthcare, Rob offers invaluable lessons and forward-thinking perspectives on life sciences and patient care innovation.

Biography:

Robert F. Williamson, III has been active in building biotechnology companies and shareholder value for over two decades. He currently is the President and COO of Triumvira Immunologics. Previously, he was the CBO of OncoMyx, an oncolytic virus company, and CEO of BioTheryX, a protein degradation therapeutics company, raising a $100M crossover round and preparing the company for an IPO. Prior to BioTheryX, Mr. Williamson served as CEO of both PharmAkea and ATXCo, oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea’s acquisition by Galecto and ATXCo’s acquisition by Blade Therapeutics. Prior, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi.

Mr. Williamson also serves as a director and adviser for foundations, private, and public companies. Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a Partner with The Boston Consulting Group and a Research Assistant for the Federal Reserve Board. He received a BA in economics from Pomona College and an MBA from Stanford.

Rob Williamson, CEO of Triumvira, on Biotech’s High-Stakes Path and Cell Therapy Innovations

Synopsis: 

In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company’s pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined solutions. Bharatt and Eric share their professional journeys and key insights, emphasizing the importance of simplicity and unwavering commitment to impactful ideas.

The episode delves into the story behind Karuna Therapeutics, highlighting the challenges of obtaining funding and skepticism from the industry before its success with a groundbreaking schizophrenia drug. Bharatt and Eric underline the importance of patient-centered innovation and reflect on the lessons learned, including overcoming obstacles with persistence. They also discuss the need for more efficient pathways in drug development and share a glimpse into PureTech’s upcoming projects.

Biography:

Bharatt Chowrira, PhD, JD, is the chief executive officer and a member of the board of directors at PureTech. Dr. Chowrira has been a member of the PureTech management team since March 2017, leading various departments including Operations, Finance and Business Development. Dr. Chowrira plays a key role in the Founded Entity fundraisings and provide strategic guidance as a Board member to many Founded Entities, including co-founding Seaport Therapeutics. Prior to joining PureTech, he held various leadership roles including Chief Executive Officer, President, Chief Operating Officer and General Counsel in multiple biotech companies over the past 30+ years, including Auspex Pharmaceuticals Inc., which was acquired by Teva Pharmaceuticals for $3.5 billion and Sirna Therapeutics that was acquired by Merck for $1.1 billion and as a Vice President at Merck & Co. Dr. Chowrira received a JD from the University of Denver’s Sturm College of Law, a PhD in molecular biology from the University of Vermont College of Medicine, an MS in molecular biology from Illinois State University and a BS in microbiology from the UAS, Bangalore, India.

Eric Elenko, PhD, is the president at PureTech where he has led the development of a number of programs, including three that have received US FDA approvals (EndeavorRx, Plenity and Cobenfy). Dr. Elenko plays a key role in the Founded Entity drug discovery and fundraisings, including co-founding Seaport Therapeutics. Prior to joining PureTech, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in biology from Swarthmore College and his PhD in biomedical sciences from the University of California, San Diego.

Bharatt Chowrira, CEO & Eric Elenko, CoFounder & President of PureTech on Biotech Growth

Synopsis: 

Host Rahul Chaturvedi leads an insightful conversation with Dr. Kristin Yarema, President and CEO of Poseida Therapeutics. Kristin shares the inspiring journey of her career, from her roots in science to leadership roles in big pharma, culminating in her move to biotech entrepreneurship. She reflects on pivotal experiences at Novartis and Amgen, her deep-seated passion for oncology and autoimmune diseases, and the exciting leap into the field of cell therapy.

Kristin unveils Poseida’s innovative genetic engineering toolkit and the company’s advancements in allogeneic cell therapies, spotlighting their potential to revolutionize treatment for conditions like multiple myeloma. She delves into the challenges and opportunities within the cell therapy space, underscoring Poseida's strategic partnerships and commitment to transformative solutions. With candid reflections on the lessons learned as a first-time CEO, Kristin offers valuable insights on fostering cohesive company culture and shares career advice for aspiring biotech professionals.

An essential listen for anyone drawn to biotech innovation, the future of cell therapy, and leadership strategies at the intersection of cutting-edge technology and patient care.

Biography:

Dr. Yarema was appointed President and Chief Executive Officer of Poseida and named to the Board of Directors in January 2024. She joined Poseida as President, Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. Prior to Poseida she served as Chief Commercial Officer at Atara Biotherapeutics, where she led the commercialization of EBVALLO™️, which became the world’s first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma. Previously Dr. Yarema held a series of U.S. and global commercial leadership roles at Amgen, including most recently Vice President & Therapeutic Area Head for Global Product Strategy & Commercial Innovation in Hematology-Oncology. Earlier in her career, Dr. Yarema worked at Novartis and McKinsey & Company. Dr. Yarema holds a Ph.D. in Chemical Engineering from University of California, Berkeley and is a graduate of Stanford University, where she earned a B.S. in Chemical Engineering and a B.A. in English. She is an officer and member of the board of directors of the Alliance for Regenerative Medicine and serves on the board of directors of the Celiac Disease Foundation.

Pioneering Advances in Cell Therapy: Kristin Yarema, President & CEO of Poseida Therapeutics

Synopsis: 

Join host Alok Tayi as he welcomes David Meeker, CEO of Rhythm Pharmaceuticals, for an inspiring conversation on the transformative journey of rare disease biotech. David shares his incredible path from practicing physician to biotech visionary, recounting his experiences at Genzyme, where he helped shape the rare disease business model and set the stage for a wave of life-changing innovations.  

In this episode, David dives deep into the breakthroughs and hurdles of developing therapies for rare diseases, the pivotal role of patient-centric approaches, and how advancements in precision medicine are reshaping treatment for conditions like genetic obesity. He also explores the evolving relationship between biotech and big pharma, the critical impact of regulatory decisions, and the essential elements of building a thriving biotech company today.  

Don’t miss this captivating discussion packed with actionable insights, industry wisdom, and a look at the future of rare disease therapeutics.

Biography:

Dr. David Meeker, a member of Rhythm’s Board of Directors since 2015 and Chairman of the Board since 2017, was appointed President and Chief Executive Officer of the Company in July 2020. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years. Previously, David was the Executive Vice President and Head of Sanofi Genzyme, the specialty-care global business unit of Sanofi that focused on rare diseases, multiple sclerosis, oncology, and immunology. He joined Genzyme in 1994 as Medical Director and, over the course of his tenure, served the company as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. He led Genzyme’s commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme® and Myozyme®. Prior to his tenure with Genzyme, David was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker earned his MD from the University of Vermont Medical School and completed the advanced management program at Harvard Business School.

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Synopsis: 

In this episode of Biotech 2050, host Alok Tayi explores the world of biotech venture capital with Narayan Chowdhury, Co-Founder of Franklin Park. As a key player in funding the next wave of biotech breakthroughs, Narayan shares how limited partners (LPs) navigate risk, identify high-potential biotech funds, and decide where to allocate billions in capital.

Discover why biotech investing is different from tech VC, the growing role of AI in drug development, and how emerging biotech hubs are shaping the future of innovation. Whether you're a founder, investor, or just biotech-curious, this episode unveils the strategies, challenges, and untapped opportunities that fuel the industry.


Biography:

At Franklin Park, Narayan is responsible for the analysis and evaluation of private equity investment opportunities, monitoring clients’ portfolios and conducting industry research. He is also involved in the development and implementation of Franklin Park’s technology platform, and regularly interacts with clients on investment and portfolio matters.

Prior to Franklin Park, Narayan worked with Hamilton Lane and Public Financial Management.  He is a CFA Charterholder and a member of the CFA Institute. Narayan received a B.A. in Mathematics and Economics from Bucknell University.

Biotech Venture Investing with Narayan Chowdhury, Co-Founder of Franklin Park LLC

Synopsis: 

In this special episode of Biotech 2050, Host Alok Tayi, CEO and Co-Founder of VibeBio, delves into the world of neurodivergent entrepreneurship and impact investing with guest Chad Belinsky, founder of AtypicalPath.org. Chad shares his inspiring journey from running a transformative B2B materials company to establishing Atypical Path—a nonprofit dedicated to supporting neurodiverse individuals, fostering mentorship, and creating impact-driven investment opportunities. Together, they explore the unique perspectives neurodivergent individuals bring to innovation, the importance of self-awareness, and how capital can drive meaningful societal change. A must-listen for those interested in mission-oriented investment, entrepreneurship, and the untapped potential of neurodivergent talent.  

Biography:

“Dumb” dyslexic, awkward aspie kid, empowered by love & tech, transformed himself and a bootstrapped family material science B2B into a 20 year overnight success with PE platform exit.

Now stewarding the proceeds & sharing forward learnings through developing AtypicalPath.org , an entrepreneurial nonprofit community where accomplished neuro-atypical earnest entrepreneurs inspire each other to compound social & economic good, while sharing forward opportunity for the next generation to thrive, through shared wisdom, contacts, grants & impact investment.

Empowering Neurodivergent Innovators: Chad Belinsky on Impact, Mentorship, and Atypical Path

Synopsis: 

Venture capital is evolving, and so is biotech. In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of VibeBio, sits down with Alex Bangash, Founder of Transpose, an investment firm backing both startups and funds.
With over 20 years of experience in venture investing, Alex shares his unconventional journey from engineering to investing and how his unique perspective has shaped his approach to funding. He breaks down the shifting startup landscape, the critical role of LPs in biotech, and why AI is a game-changer for both tech and life sciences.
Alex also offers sharp insights into what it takes to build a successful venture fund today and the structural shifts that are redefining the industry. Whether you're a founder, investor, or biotech enthusiast, this episode is packed with valuable lessons on navigating the future of venture capital.

Biography:

Alex Bangash is the Founder of Transpose Platform, an anchor fund for the most disruptive venture funds of this decade. He is also the co-founder and former CEO of Trusted Insight, a machine learning–driven platform that hosts the world’s largest network of institutional investors. Prior to TI Platform, Alex managed capital for clients at premier endowments, foundations, family offices, insurance firms, sovereign wealth funds, and pension funds since 2003. He has helped invest over $2 billion in 50 funds with a track record of investing over $1 billion in 50+ funds for institutional investors with an IRR of 30%+ and a 2x NAV. He advised the first checks in Accel, First Round Capital, Founders Fund, Emergence, Y Combinator, Khosla, SaaStr, Initialized, Crystal Towers, and Baseline. Earlier in his career, Alex was an engineer and executive at AT&T, Lucent Technologies, Bell Labs, and GE. Alex holds an MBA from the Wharton School (where he is a frequent guest lecturer); an M.Eng. in Operations Research from Cornell, and a BS in Computer Science, English, and Economics from Cornell.

AI, Biotech, & Venture Capital: Alex Bangash, Founder of Transpose, on Future of Startup Investing

Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.

New tracks tagged #BioTech2050